Skip to main content
. 2017 Oct 24;12(6):815–826. doi: 10.1007/s11523-017-0528-z

Fig. 3.

Fig. 3

Effect of ceritinib on insulin-like growth factor-1 receptor (IGF1R) signaling in ARMS and ERMS cell lines. a Effects of ceritinib treatment on pIGF1R, pAkt, and pS6 by PathScan analysis. Relative phosphorylation is shown. b Endogenous IGF1R and pIGF1R expression in ARMS and ERMS cell lines as determined by Western Blot analysis ((p) IGF1R = 95 kDa). c Confirmation of the effects of ceritinib treatment on pIGF1R, pAkt, and pS6 by Western Blot analysis (pAkt = 60 kDa, pS6 = 32 kDa). Untreated cells (−) were compared to cells treated with 2.5 μM ceritinib for 24 h (+). d ALK and IGF1R expression in the Rh41, RD, and Aska cell line in either untreated (−), scrambled siRNA (NT) treated, or ALK/IGF1R siRNA (ALK/IGF1R) treated cells determined by Western Blot analysis. e Relative cell viability following NT, ALK, or IGF1R siRNA treatment in the Rh41, RD and Aska cell lines. Effects on cell viability were determined in triplicate and untreated (control) cells were set at 1.0. *p < 0.05, **p < 0.01, ***p < 0.001